ASX Announcements


 
    Appendix 4D and FY24 Half Year Financial Report  
 
    INOVIQ detects 19% more breast cancers than leading test  
 
    Appendix 4C and Quarterly Activities Report - December 2023  
 
    2023 AGM Results of Meeting  
 
    2023 AGM CEO Presentation  
 
    Bell Potter Healthcare Conference Investor Presentation  
 
    ANSEV Meeting Presentations  
 
    Appendix 4C and Quarterly Activities Report - September 2023  
 
    Notice of Annual General Meeting/Proxy Form  
 
    INOVIQ Board expanded - David Williams to become Chairman  
 
    2023 Annual Report  
 
    ASX Small and Mid-Cap Conference Investor Presentation  
 
    IFPA 2023 Conference Presentation and Award for INOVIQ CSO  
 
    IIQ and ResearchDx sign USA EXO-NET Services Agreement  
 
    Appendix 4E and Preliminary Financial Report  
 
    EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY  
 
    INOVIQ Investor Briefing  
 
    Appendix 4C and Quarterly Activities Report - June 2023  
 
    INOVIQ and Promega announce Global Joint Marketing Agreement  
 
    SubB2M/CA15.3 Clinical Validation Data Investor Presentation  
 
    INOVIQ Investor Briefing  
 
    Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test  
 
    ISEV Meeting Presentations  
 
    Appendix 4C and Quarterly Activities Report - March 2023  
 
    INOVIQ to present new EXO-NET data at ISEV Annual Meeting  
 
    Appendix 4D and Half Year Financial Report  
 
    Positive results for SubB2M Breast Cancer Test  
 
    Appendix 4C & Quarterly Activities Report - December 2022  
 
    Resignation of Director  
 
    Positive EXO-NET Results in Ovarian Cancer  
 
    MST Access Diagnostics Forum Presentation  
 
    Change in substantial holding  
 
    Results of 2022 Annual General Meeting  
 
    CEO AGM Presentation  
 
    INOVIQ Settles Legal Proceedings  
 
    Commercial and R&D Update  
 
    Healthcare Conference Investor Presentation  
 
    Appendix 4C - Statement pursuant to Listing Rule 4.7C.3  
 
    IIQ Appendix 4C & Quarterly Activities Report-September 2022  
 
    Canadian Patent Granted for BARD1 Technology  
 
    Investor Presentation  
 
    Notice of Annual General Meeting  
 
    Receipt of R&D Tax Incentive Refund  
 
    INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appointment/Resignation of CFO and Company Secretary  
 
    Notification of cessation of securities - IIQ  
 
    Notice required under listing rule 3.13.1  
 
    2022 Annual Report and update on results  
 
    Appendix 4E and Preliminary Financial Report  
 
    IIQ Investor Presentation  
 
    INOVIQ Investor Briefing Invitation - June 2022 Quarter  
 
    IIQ Appendix 4C & Quarterly Activities Report - June 2022  
 
    Positive SubB2M IHC Results for Melanoma  
 
    hTERT US Patent Granted  
 
    INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out  
 
    SubB2M US Patent Grant and Program Update  
 
    INOVIQ&University of Sydney Present New EXO-NET Data at ISEV  
 
    Change of Director's Interest - Philip Powell  
 
    IIQ Investor Presentation  
 
    Change of Director's Interest - Dr Geoffrey Cumming  
 
    Change of Director's Interest - Philip Powell  
 
    INOVIQ Investor Briefing Invitation  
 
    Australian Patent Granted for SubB2M Technology  
 
    INOVIQ Key Manufacturing Agreement to Advance SubB2M tests  
 
    IIQ Appendix 4C & Quarterly Activities Report - March 2022  
 
    INOVIQ CSO Co-Authors Scientific Statement on Exosomes  
 
    Notification of cessation of securities - IIQ  
 
    Updated Investor Presentation  
 
    SubB2M Paper Published in BMC Cancer Journal  
 
    INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests  
 
    INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test  
 
    Update on Legal Proceedings and BARD1 Autoantibody Program  
 
    Appendix 4D and Half Year Financial Report  
 
    Brazilian Patent Issued for Lung & Colorectal Cancer  
 
    Updated Investor Presentation  
 
    Notification regarding unquoted securities - IIQ  
 
    Appendix 4C & Quarterly Activities Report  
 
    US Patent Issued - BARD1 Breast & Ovarian Cancer Diagnosis  
 
    INOVIQ Awarded Additional BTB Funding to Develop SubB2M test  
 
    INOVIQ Appendix 4G and Corporate Governance Statement  
 
    Chinese Patent Issued in BARD1 Patent Family for Lung Cancer  
 
    Appendix 3Y - Change of Director's Interest Notice x 4  
 
    Notification regarding unquoted securities - IIQ  
 
    BARD1 Changes its Name to INOVIQ  
 
    Cleansing Notice - Issued of Four Shares - Resolution 5 AGM  
 
    Application for quotation of securities - BD1  
 
    Application for quotation of securities - BD1  
 
    Results of 2021 Annual General Meeting  
 
    AGM Presentation  
 
    New BARD1 Exosome Liquid Biopsy Project  
 
    Application for quotation of securities - BD1  
 
    Notification regarding unquoted securities - BD1  
 
    US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis  
 
    EXO-NET ANZSEV Presentation  
 
    BARD1 Presenting at Bell Potter Healthcare Conference  
 
    EXO-NET Presented at Virtual ANZSEV Symposium  
 
    Jobkeeper Payment Notification  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Ceasing to be a substantial holder  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4C & Quarterly Activities Report  
 
    Change of Director's Interest - Philip Powell  
 
    Amended Remuneration Table Directors Report  
 
    Notice required under listing rule 3.13.1  
 
    Notification of cessation of securities - BD1  
 
    2021 Annual Report  
 
    BARD1 Appoints New CSO  
 
    Notification of cessation of securities - BD1  
 
    Appendix 4E and Preliminary Financial Report  
 
    Change in substantial holding  
 
    Change of Director's Interest - Powell  
 
    Change of Director's Interest - Dr Geoffrey Cumming  
 
    Change of Director's Interest - Johnston  
 
    Notification of cessation of securities - BD1  
 
    Appendix 2A  
 
    BARD1 Share Purchase Plan Completed Oversubscribed  
 
    Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test  
 
    BARD1 LODGES SPP AND OPTIONS PROSPECTUS  
 
    Appendix 4C & Quarterly Activities Report  
 
    Appendix 2A  
 
    BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data  
 
    Updated Investor Presentation  
 
    Terms of issue of Options  
 
    Investor Presentation  
 
    Appendix 3B  
 
    BARD1 $15m Placement to Accelerate Cancer Diagnostic Program  
 
    Trading Halt  
 
    BARD1 Investor Presentation  
 
    BARD1 Autoantibody Test Results for Ovarian Cancer Published  
 
    SubB2M Breast Cancer Test Manuscript Submitted  
 
    Update on Legal Proceedings  
 
    R&D Tax Incentive Refund Received  
 
    BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test  
 
    BARD1 Files Two New Patents Protecting SubB2M & EXO-NET  
 
    BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference  
 
    BARD1 Launches its RUO EXO-NET Product  
 
    Appendix 4C and Quarterly Activities Report  
 
    Positive Results from the BARD1 Autoantibody Assay  
 
    Appendix 3G - Long Term Incentive Options Issued to CEO  
 
    BARD1 Signs Option Agreement for Type 3C Diabetes Test  
 
    Appendix 2A  
 
    Positive Results Evaluation of EXO-NET in Pancreatic Cancer  
 
    Appendix 2A  
 
    Australian Patent Granted for hTERT  
 
    BARD1 Achieves hTERT Registration and First Order in Korea  
 
    Appendix 2A  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder  
 
    Appendix 4D and Half-year financial report  
 
    Commencement of Legal Proceedings Against BARD1  
 
    Appendix 2A  
 
    Ceasing to be a substantial holder  
 
    Becoming a substantial holder  
 
    Excellent SubB2M Breast Cancer Test Data  
 
    Outstanding SubB2M Ovarian Cancer Test Data  
 
    Change of Auditor  
 
    Appendix 4C & Quarterly Activities Report  
 
    U.S. Patent Granted for NET Technology for Exosome Capture  
 
    Final Director's Interest Notice - Dr Irminger-Finger  
 
    Dr Irminger steps down from Board, continues as Consultant  
 
    Change of Director's Interest Notice - Cumming  
 
    Change of Director's Interest Notice - Powell  
 
    Change of Director's Interest Notice - Johnston  
 
    Final Director's Interest Notice - Helen Fisher  
 
    Patent Granted in China for hTERT  
 
    Further Detail on BARD1's US Sales Strategy  
 
    Trading Halt  
 
    Pause in Trading  
 
    Results of Meeting  
 
    AGM & CEO Presentations and Chairman's Transcript  
 
    Consolidation/Split - BD1  
 
    Helen Fisher Steps Down from BARD1 Board  
 
    BARD1 Gains New High-volume Customer for its hTERT Test  
 
    Appendix 4C and Quarterly Activities Report  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Notice of AGM ASX Listing Rule 3.13.1  
 
    Successful BARD1 Kit Evaluation  
 
    BARD1 Awarded BTB Funding to Develop Breast Cancer Test  
 
    Revised Securities Trading Policy  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and Annual Report to Shareholders  
 
    Change of Director's Interest - Helen Fisher  
 
    Change of Director's Interest - Dr Geoffrey Cumming  
 
    European Patent Validated  
 
    Change in substantial holding  
 
    Initial Director's Interest Notice - Fisher  
 
    Initial Director's Interest Notice - Cumming  
 
    Change of Director's Interest Notice - Powell  
 
    Change of Director's Interest Notice - Johnston  
 
    Final Directors Interest - Gunzburg  
 
    Change in substantial holding  
 
    Quarterly Business Update & Appendix 4C  
 
    Appendix 2A - Issue of Scheme Shares  
 
    BARD1 COMPLETES SIENNA ACQUISITION  
 
    SDX: Implementation of Scheme of Arrangement  
 
    Appointment of Chief Scientific Officer  
 
    Quarterly Activities Report & Appendix 4C  
 
    Receipt of R&D Tax Incentive Refund  
 
    BARD1 Signs Contract with Griffith University  
 
    Half Yearly Report and Accounts  
 
    Appendix 4C Quarterly Cashflow Report  
 
    Appendix 3Y - Cripps  
 
    Director Appointment  
 
    Details of Company Address  
 
    Appendix 3B  
 
    Appendix 3Y - Irminger-Finger  
 
    Constitution  
 
    Results of Meeting  
 
    AGM Presentation  
 
    Appendix 4C - quarterly  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 3Y - Irminger-Finger  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Phase 3 Assay Development Milestone Reached  
 
    Appendix 3B  
 
    Long Term Incentives for CEO  
 
    Appendix 3Y - Irminger-Finger  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and Annual Report to Shareholders  
 
    Quarterly Business Update and Appendix 4C  
 
    Change in Substantial Shareholding - Irminger-Finger  
 
    Appendix 3Y - Powell  
 
    Appendix 3Y - Johnston  
 
    Appendix 3Y - Irminger-Finger  
 
    Appendix 3Y - Gunzburg  
 
    Completion of Capital Raising Package  
 
    Appendix 3B and Cleansing Notice 708A  
 
    Closure of Entitlement Offer and Shortfall Notification  
 
    Progress on Assay Development Program  
 
    Despatch of Offer Document  
 
    603 SSN - Merchant Funds Management Pty Ltd  
 
    603 SSN - Jeffrey Emmanuel  
 
    603 Initial SSN - Moggs Creek Pty Ltd ATF Moggs Creek S/F  
 
    Letters to Shareholders  
 
    Appendix 3X - Powell  
 
    Appendix 3X - Johnston  
 
    Appendix 3Z - Montgomery  
 
    Letter to Optionholders  
 
    Cleansing Notice Section 708(AA)  
 
    Cleansing Notice Section 708(A)  
 
    Offer Document  
 
    Appendix 3B  
 
    Capital Raising and Board Changes  
 
    Trading Halt  
 
    EUROPEAN PATENT VALIDATED  
 
    R&D Tax Incentive Refund  
 
    U.S. Patent Issued  
 
    Appendix 4C - quarterly  
 
    Response to ASX Price and Volume Query  
 
    Half Yearly Report and Accounts  
 
    Cancer Vaccine Study Results  
 
    Quarterly Business Update and Appendix 4C  
 
    Change in Substantial Holding  
 
    Change of Directors Interest - Irminger-Finger  
 
    Change of Directors Interest - Montgomery  
 
    Change of Directors Interest - Gunzburg  
 
    Shortfall Confirmation and Appendix 3B  
 
    Closure of Entitlement Offer and Shortfall  
 
    Change of Director's Interest Notice  
 
    Results of Meeting  
 
    AGM Presentation  
 
    Despatch of Offer Document  
 
    Letters to Shareholders  
 
    Appendix 3B  
 
    Cleansing Notice Rights Issue  
 
    Rights Offer Document  
 
    Company Presentation  
 
    Appendix 3B  
 
    Capital Raising Indicative Timetable  
 
    Non-Renounceable Issue  
 
    Trading Halt  
 
    Pause In Trading  
 
    Ceasing to be a substantial holder  
 
    Quarterly Activities Report and Cashflow  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Grant of Additional Chinese Patent Core BARD1 Patent Family  
 
    Development of world first BARD1 Breast Cancer Test  
 
    Appendix 4G  
 
    Annual Report to Shareholders  
 
    Investor Presentation and Update  
 
    Ceasing to be a substantial holder  
 
    Bard1 Ovarian Test Results  
 
    Appendix 4E  
 
    Final Director's Interest Notice  
 
    Death of Non-Executive Director  
 
    Quarterly Activities Report and Appendix 4C  
 
    US Patent Issued Protecting BARD1 Ovarian Test  
 
    Appendix 3B Release of Securities from Escrow  
 
    Improved Performance of BARD1 Ovarian Test  
 
    Notice under ASX Listing Rule 3.10A  
 
    Reinstatement to Official Quotation  
 
    Response to ASX Price Query  
 
    Contract Development Agreement Signed  
 
    Voluntary Suspension  
 
    Trading Halt  
 
    Quarterly Business Update and Appendix 4C  
 
    Becoming a substantial holder  
 
    Appendix 3B and Cleansing Statement  
 
    Corporate Presentation  
 
    Capital Raising  
 
    Israeli Patent Issued in Bard1 Core Patent Family  
 
    Trading Halt  
 
    Additional BARD1 Ovarian Test Results  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B (Advisor Options)  
 
    Grant of Japanese Patent  
 
    Quarterly Business Update and Appendix 4C  
 
    RESULTS OF BARD1 OVARIAN CANCER STUDY  
 
    Results of Meeting  
 
    AGM Presentation  
 
    Quarterly Business Update and Appendix 4C  
 
    Notice of Annual General Meeting  
 
    Research and Development Update  
 
    Appendix 4G  
 
    Annual Report to Shareholders  
 
    Appendix 4E Preliminary Financial Results  
 
    Publication of BARD1 Lung Cancer Test  
 
    Appendix 3B  
 
    Australian Patent Issued  
 
    Completion of Share Purchase Plan  
 
    Quarterly Activities Report & Appendix 4C  
 
    Appointment of Dr Samuel Janes  
 
    Completion of Capital Raising  
 
    Appendix 3B and Cleansing Notice  
 
    Share Purchase Plan Cleansing Statement  
 
    Share Purchase Plan Document  
 
    Capital Raising  
 
    Trading Halt  
 
    Shareholder Update  
 
    Lung Cancer Study Results  
 
    Quarterly Activities Report and Appendix 4C  
 
    Shareholder Update  
 
    Cancer Vaccine Collaboration  
 
    Appendix 3B  
 
    OVARIAN CANCER CLINICAL STUDY RESULTS  
 
    GRANT OF U.S. PATENT  
 
    Appendix 4D and Half Yearly Reports and Accounts  
 
    Successful Assay Feasibility Results  
 
    Quarterly Activities Review and Appendix 4C  
 
    CEO Terms of Employment  
 
    AGM RESULTS  
 
    AGM PRESENTATION  
 
    Appointment of CEO  
 
    Quarterly Activities Report and Appendix 4C  
 
    Appendix 4G  
 
    Annual Report to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Statutory Audited Financial Statements  
 
    Company Update - Promising Result for Ovarian Cancer  
 
    Preliminary Final Report - Appendix 4E  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Quarterly Activities Report and Appendix 4C  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Becoming a Substantial Holder - Walker  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Becoming a substantial holder  
 
    Confirmations to ASX  
 
    Terms of Securities  
 
    Confirmation in relation to restricted securities  
 
    Securities Trading Policy  
 
    Use of Funds Information  
 
    Pro-forma Statement of Financial Position  
 
    BARD1AG Financial Statements 2015  
 
    BARD1AG Financial Statements 2014  
 
    BARD1AG Financial Statements 2013  
 
    Constitution  
 
    Appendix 1A and Information Form & Checklist  
 
    Capital Structure  
 
    Top 20 Shareholders  
 
    Distribution Schedule  
 
    Pre-reinstatement Disclosure  
 
    ASX Notice  
 
    Reinstatement to Official Quotation - 20 June 2016  
 
    Appendix 3Z - Collinson  
 
    Appendix 3X - Laurent  
 
    Appendix 3X - Irminger  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3B  
 
    Receipt of Signed Restriction Agreement  
 
    Extension to deadline for automatic removal  
 
    Capital Raising Closed Oversubscribed  
 
    Quarterly Activities Report and App 5B  
 
    Replacement Prospectus  
 
    Results of Meeting  
 
    PROSPECTUS  
 
    Notice of General Meeting  
 
    Quarterly Activities Report and Appendix 5B  
 
    Half Year Accounts  
 
    Proposed Acquisition and Capital Raising  
 
    Results of Annual General Meeting  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Quarterly Activities and Cashflow Report  
 
    Full Year Statutory Accounts  
 
    Quarterly Activities and Cashflow Report  
 
    Details of Share Registry address  
 
    Quarterly Cashflow & Activities Report  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Quarterly Activities Report and Cashflow  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Top 20 securityholders  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Updated Timetable Non-Renounceable Rights Issue  
 
    Extension of Non-Renounceable Rights Issue  
 
    Despatch of Non-Renounceable Rights Issue Prospectus  
 
    Letter to Ineligible Shareholders  
 
    Letter to Eligible Shareholders  
 
    Results of Meeting  
 
    Becoming a substantial holder  
 
    Appendix 3B  
 
    Prospectus  
 
    Substantial Shareholders Notice - Montgomery  
 
    Becoming a Substantial Shareholder - Cheung  
 
    Ceasing to be a substantial holder  
 
    Change of Director's Interest - Gunzburg  
 
    Initial Director's Interest - Collinson  
 
    Initial Director's Interest - Montgomery  
 
    Final Directors' Interests - Dew-Procter-Wong  
 
    Company Update  
 
    Annual Report to Shareholders  
 
    Quarterly Activities and Cashflow Report  
 
    Notice of AGM and Proxy Form  
 
    Completion of Dragon Share Offer  
 
    Full Year Statutory Accounts  
 
    Offer Document  
 
    Sale of Shares in Dragon Mining  
 
    Company Update  
 
    Quarterly Cashflow and Activities Report  
 
    Quarterly Cashflow and Activities Report  
 
    Half Year Accounts  
 
    Takeovers Panel Decision (Dragon Mining)  
 
    Quarterly Activities and Cashflow Report  
 
    Company Update  
 
    Results of Meeting  
 
    Quarterly Cashflow and Activities Report  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Full Year Statutory Accounts  
 
    Quarterly Cashflow and Activities Report  
 
    Company Update  
 
    Suspension from Official Quotation  
 
    Trading Halt Request  
 
    Trading Halt  
 
    Company Update  
 
    Quarterly Activities Report and Cashflow  
 
    Change of Director's Interest Notice  
 
    Half Year Accounts  
 
    Quarterly Activities and Cashflow Report  
 
    New Contact Numbers  
 
    Details of Company Address  
 
    Initial Director's (Alternate) Interest Notice  
 
    Appointment of Alternate Director  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Director Appointment/Resignation  
 
    Results of Meeting  
 
    Reinstatement to Official Quotation  
 
    Annual Report to shareholders  
 
    Quarterly Cashflow and Activities Report  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Director Appointment/Resignation  
 
    Full Year Statutory Accounts  
 
    Quarterly Activities and Appendix 5B  
 
    Quarterly Activities and Cashflow Report  
 
    Company Update - Dragon Mining Ltd Rights Issue  
 
    Revised Half Yearly Report and Financials  
 
    Half Yearly Report and Accounts  
 
    Company Update  
 
    Dragon Mining Rights Issue Subunderwriting  
 
    Quarterly Cashflow and Activities Report  
 
    Results of Meeting  
 
    Change in substantial holding  
 
    Annual Report to shareholders  
 
    Quarterly Activities and Cashflow Report  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Amended Directors Interest Amended  
 
    Change of Director's Interest Notice  
 
    Full Year Statutory Accounts  
 
    Full Year Statutory Accounts  
 
    Becoming a substantial holder  
 
    Quarterly Activities and Cashflow Report  
 
    Quarterly Cashflow and Activities Report  
 
    Change of Director's Interest Notice  
 
    Half Yearly Report and Accounts  
 
    Change of Director's Interest Notice  
 
    Half Yearly Accounts  
 
    Revised Quarterly Appendix 5B  
 
    Quarterly Cashflow and Activities Reports  
 
    Letter to Shareholders re Unmarketable Parcel of Shares  
 
    Securities Trading Policy  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 3B  
 
    Brinkley Mining Takeover  
 
    Results of Annual General Meeting  
 
    Results of General Meeting  
 
    Quarterly Cashflow Report - Replacement  
 
    Acquisition of Brinkley Mining Plc by Scheme of Arrangement  
 
    Quarterly Activities and Appendix 5B  
 
    Annual Report to shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Notice of General Meeting/Proxy Form  
 
    Acquisition of Brinkley Mining PLC by Scheme of Arrangement  
 
    Full Year Statutory Accounts  
 
    Repayment of Loan by Tanami Gold NL  
 
    Quarterly Cashflow and Activities Report  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Quarterly Cashflow Report  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    A$5 million loan facility toTanami Gold NL  
 
    Half Yearly Accounts  
 
    Interest in Brinkley Mining Plc  
 
    Quarterly Activities Report and Appendix 5B  
 
    Brinkley Mining/Eurogold interest in Dragon Mining Limited  
 
    Brinkley Mining Plc Minority interest in Dragon Mining Ltd  
 
    Results of Meeting  
 
    Annual Report to shareholders  
 
    Updated Net Asset Position  
 
    Change in substantial holding  
 
    September 2009 Quarterly Cashflow and Activities Report  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Full Year Statutory Accounts  
 
    Investment in Brinkley Mining PLC  
 
    Quarterly Cashflow Report  
 
    Response to ASX Query re Appendix 3Y  
 
    Change of Director's Interest Notice  
 
    Update on recent activities  
 
    Request for Trading Halt  
 
    Trading Halt  
 
    Quarterly Activities Report  
 
    Half Year Accounts  
 
    Quarterly Activities and Cashflow Report  
 
    Appendix 5B  
 
    Results of Meeting  
 
    Annual Report to shareholders  
 
    Quarterly Activities and Cashflow Reports  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change in substantial holding  
 
    Full Year Statutory Accounts  
 
    Appendix 5B - Monthly  
 
    Becoming a substantial holder  
 
    Allotment of Shares re Non-Renounceable Issue  
 
    Non-Renounceable Issue  
 
    Completion of Non-Renounceable Issue  
 
    Appendix 5B - Monthly  
 
    ASX Circular: Reorganisation of Capital  
 
    Results of Meeting  
 
    Supplementary Prospectus  
 
    Quarterly Activities Report  
 
    Change in substantial holding  
 
    Revised Timetable Non-Renounceable Rights Issue  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 5B  
 
    Notice of General Meeting/Proxy Form  
 
    Despatch of Prospectus  
 
    Non-Renounceable Rights Issue - Revised Prospectus  
 
    Letter to Shareholders  
 
    Prospectus  
 
    Non-Renounceable Rights Issue and Share Consolidation  
 
    Monthly Financials  
 
    Settlement with Oxus Gold Plc  
 
    Monthly Financials  
 
    Settlement with Oxus Gold Plc  
 
    Quarterly Activities  
 
    Settlement with Oxus Gold  
 
    Monthly Financials  
 
    Half Yearly Report and Accounts  
 
    Ceasing to be a substantial holder  
 
    Becoming a substantial holder  
 
    Ceasing to be a substantial holder  
 
    Ceasing to be a substantial holder  
 
    Settlement of Federal Court Proceedings Against Oxus Gold  
 
    Trading Halt  
 
    Monthly Financials  
 
    Quarterly Activities and Cashflow Report  
 
    Appendix 5B - Monthly  
 
    Appendix 5B  
 
    Appendix 5B  
 
    Results of Meeting  
 
    Results of Meeting  
 
    Annual Report to shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Quarterly Activities Report  
 
    Full Year Accounts  
 
    Appendix 5B  
 
    Change of Director's Interest Notice  
 
    Quarterly Activities Report  
 
    Results of Meeting  
 
    Details of Company Address  
 
    Notice of General Meeting  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Federal Court Dismissed Motion  
 
    Proposed Sale of Assets  
 
    Company's request for trading halt  
 
    Trading Halt  
 
    Third Quarter Activities & Cashflow Reports  
 
    Loan Repayment  
 
    Termination of Agreement to Purchase Saulyak Gold Mine  
 
    Half Year Accounts  
 
    Proposed Sale of Gold Assets to Dargon Mining Ltc  
 
    Second Quarter Activities & Cashflow Reports  
 
    Change in substantial holding